Ace Therapeutics provides comprehensive preclinical development services for attention deficit hyperactivity disorder (ADHD), covering the entire process from target validation, lead compound screening and optimization, to pharmacodynamic and safety assessments. With advanced platform technologies and animal models, we accurately assess the impact of drugs on ADHD-related neurobiological pathways while ensuring their safety and efficacy. Our one-stop customized solutions can help clients accelerate the development of ADHD therapeutics and drive innovative therapies to market quickly.

What Medications Can Help Treat ADHD?

Medications can help children manage their ADHD symptoms in their daily lives.

• Stimulants are the best-known and most widely used ADHD medications. With these fast-acting medications, 70-80% of children with ADHD have fewer ADHD symptoms.
• Non-stimulants were approved in 2003 for the treatment of ADHD. They do not work as fast as stimulants, but their effects can last up to 24 hours.

Note: Medications can affect children differently and may have side effects such as decreased appetite or sleep problems. A child may respond well to one medication but not to another.

How Can We Help?

Pathophysiologic Mechanism Research Services of ADHD

Ace Therapeutics assists clients in gaining a deeper understanding of the pathophysiologic mechanisms of attention deficit disorder (ADHD), including neurotransmitter systems, brain region function, and genetic factors. Our platform technologies and animal models enable us to elucidate the pathogenesis of ADHD, providing a scientific basis for ADHD diagnosis and innovative therapy development.

The pathophysiology of ADHD research services we offer focus on neuromodulation and neurochemistry.

• In neuromodulation, studies have identified abnormal activity in brain regions associated with attention and control of behavior. These brain regions include the prefrontal cortex, dorsal anterior cingulate cortex, dorsal alloptic cortex, and basal ganglia. The normal function of these regions and their interactions with each other is critical in leading to the control and regulation of behavior.
• In neurochemistry, research has found that ADHD is associated with neurotransmitter imbalances. Studies have shown that ADHD patients have lower levels of dopamine and norepinephrine in the brain and that the function of brain regions associated with attention and control of behavior is compromised.
• Genetics is also an important aspect of ADHD pathophysiology research. Studies have shown that ADHD can be inherited and that genetic mutations are associated with neurotransmission and regulation.

Preclinical Screening and Evaluation Services for ADHD Therapeutic Drugs

We offer a full range of preclinical screening and evaluation services for attention deficit disorder (ADHD) drugs, covering the entire process from target validation and compound screening to pharmacodynamic and safety evaluations. Our capabilities in drug screening and evaluation include:

• Wide range of animal models, including mouse or rat models, non-primate models.
• Flexible high-throughput screening strategies, including genetic or phenotypic screening, virtual screening and high-throughput screening.
• Advanced platform technologies can efficiently identify and optimize potential ADHD drugs, assess their safety and efficacy, and thus accelerate the translation of drugs from the laboratory to clinical applications.

Related Services

• Bipolar Disorder Animal Models
• Behavior Tests in Psychiatry
• Preclinical Imaging Services in Psychiatry
• Antipsychotics Screening Services
• Antipsychotic Discovery and Preclinical Services
• Pharmacokinetics Analysis Services for Antipsychotics

Ace Therapeutics is committed to conducting research and scientific evaluations from multiple perspectives to accelerate your efforts in the development of drugs for ADHD. If you are interested in our services, please contact us to learn how we can support you in your project.